Aberdeen Group
GPCR icon

Aberdeen Group’s Structure Therapeutics GPCR Stock Holding History

Aberdeen Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3M Buy
639,915
+248,106
+63% +$11M 0.05% 301
2026
Q1 		$18.9M Buy
391,809
+126,940
+48% +$8.69M 0.03% 444
2025
Q4 		$18.4M Sell
264,869
-322,000
-55% -$13.1M 0.03% 461
2025
Q3 		$16.4M Buy
586,869
+185,245
+46% +$3.69M 0.03% 494
2025
Q2 		$8.33M Buy
401,624
+152,725
+61% +$3.36M 0.01% 638
2025
Q1 		$4.31M Buy
248,899
+77,511
+45% +$1.9M 0.01% 694
2024
Q4 		$4.65M Sell
171,388
-45,695
-21% -$1.62M 0.01% 661
2024
Q3 		$9.53M Buy
217,083
+123,789
+133% +$4.79M 0.02% 530
2024
Q2 		$3.66M Buy
+93,294
New +$3.83M 0.01% 682

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Aberdeen Group's GPCR Position: Q2 2026 in Review

Aberdeen Group increased its Structure Therapeutics (GPCR) stake by 63% in Q2 2026, buying an estimated $11M and bringing the position to 639,915 shares worth $34.3M. The position accounts for 0.05% of the portfolio, ranked #301.

Aberdeen Group first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Aberdeen Group held 639,915 shares of Structure Therapeutics worth $34.3M as of Q2 2026.
  • Aberdeen Group bought 248,106 Structure Therapeutics shares in Q2 2026, an estimated $11M.
  • Structure Therapeutics made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #301 holding.
  • Aberdeen Group first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.